Stream
Stories
-
FDA approves first drug to treat adults with primary membranous nephropathy
The FDA approved Gazyva (obinutuzumab) injection for adults with primary membranous nephropathy at risk of disease progression to induce remission of proteinuria. In the MAJESTY Phase 3 study, 36% of patients achieved complete remission at week 104 versus 6% with tacrolimus.
-
FDA approves durvalumab with enfortumab vedotin-ejfv for muscle invasive bladder cancer
On November 13, 2026, the FDA approved durvalumab (Imfinzi, AstraZeneca) in combination with enfortumab vedotin-ejfv as neoadjuvant treatment followed by single-agent durvalumab as adjuvant therapy after radical cystectomy for adult patients with muscle invasive bladder cancer who are ineligible for or have refused cisplatin-based chemotherapy. The approval was granted under priority review and six weeks ahead of the FDA goal date.
-
Novatek registers Phase 2/3 trial of NP-101 in GEP-NECs
The study, led by Novatek Pharmaceuticals, plans to enroll an estimate of 381 participants to evaluate the safety and efficacy of NP-101 combined with Nivolumab and Ipilimumab versus placebo in refractory advanced and metastatic gastroenteropancreatic neuroendocrine carcinomas. It is planned to begin in January 2027 and reach primary completion in December 2029.
-
AstraZeneca registers Phase 3 trial of Symbicort Aerosphere in children
The study plans to enroll 216 participants aged 4 to <12 years and start on October 30, 2026. It plans to compare BFF MDI 80/4.8 μg 2 actuations BID to BD MDI 80 μg 2 actuations BID over 6 weeks to assess lung function and safety.
-
RemeGen registers Phase IIIb trial of RC28-E Injection in DME and wAMD
The study, led by RemeGen Co., Ltd., plans to enroll 350 participants and has a planned start date of October 30, 2026. It aims to evaluate the safety profile and explore the efficacy of RC28-E in participants with diabetic macular edema and wet age-related macular degeneration.
-
RemeGen registers Phase II/III study of RC118 plus RC148 for claudin 18.2-positive gastric cancer
The study, led by RemeGen Co., Ltd., plans to enroll 680 participants and plans to start in November 2026, with primary completion projected for April 30, 2030. It compares RC118/RC148 combinations to Tislelizumab plus CAPOX as first-line therapy for HER2-negative, claudin 18.2-positive gastric or gastroesophageal junction adenocarcinoma.
-
Janssen posts results of Phase 3 seltorexant trial in major depressive disorder with insomnia
The study enrolled 757 participants and began on September 15, 2020, with primary completion on October 3, 2023. It compared seltorexant 20 mg to quetiapine XR as adjunctive therapy to antidepressants in adults and elderly patients with major depressive disorder with insomnia symptoms who had responded inadequately to antidepressant therapy.
-
AbbVie posts results of Phase 3b TRITON study of Bimatoprost SR in glaucoma
The trial enrolled 515 participants and completed primary data collection on August 8, 2025. It evaluated the duration of intraocular pressure-lowering effect and safety of as-needed Bimatoprost SR in participants with open-angle glaucoma or ocular hypertension not adequately managed with topical IOP-lowering medication.
-
Harmony Biosciences posts results of Phase 3 pitolisant study in idiopathic hypersomnia
Results for the open-label study were first posted on ClinicalTrials.gov on November 13, 2026. The completed study enrolled 119 participants and assessed the long-term safety and effectiveness of pitolisant after the double-blind randomized withdrawal phase of HBS-101-CL-010.
-
Authors find no link between engraftment microbiome diversity and non-relapse mortality
The authors of a Phase III trial published in Nature Medicine reported no association between engraftment microbiome diversity and non-relapse mortality after 1 year (P = 0.314). They also found that lower baseline microbiome diversity was associated with shorter overall survival (P = 0.007).
-
EMA recommends approval of seven new medicines at CHMP meeting
The Committee for Medicinal Products for Human Use (CHMP) recommended granting marketing authorization for Aumseqa, Baxfendy, Zybrivo, Garzulys, Donrafylix, Fondaparinux sodium Evumed, and Ruxolitinib Krka. The recommendations cover treatments for non-small cell lung cancer, hypertension, non-squamous non-small cell lung cancer, diabetes, venous thromboembolism, and myelofibrosis, among others.
-
CHMP adopts positive opinion on Zybrivo for non-squamous NSCLC
On 12 November 2026 the CHMP recommended granting a marketing authorization for Zybrivo, a sintilimab-based therapy, for first-line treatment of adult non-squamous non-small cell lung cancer. The recommendation follows a randomised, multicentre, double-blind, placebo-controlled study showing improved progression-free survival when sintilimab is combined with chemotherapy.